Biogen BIIB
Biogen is a biopharmaceutical company that develops and commercializes therapies for neurological diseases, such as multiple sclerosis and Alzheimer's, with a business model based on innovation and the sale of prescription drugs. Biogen shows solid financial health (score 7.16) and strong momentum (8.94), but its growth is negative (-84.8% in earnings) and its valuation is demanding (P/E 40.5). Progress in its pipeline, especially LEQEMBI and kidney disease data, is positive, but regulatory risk in the pharmaceutical sector is a drag.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Biogen is a biopharmaceutical company that develops and commercializes therapies for neurological diseases, such as multiple sclerosis and Alzheimer's, with a business model based on innovation and the sale of prescription drugs. Biogen shows solid financial health (score 7.16) and strong momentum (8.94), but its growth is negative (-84.8% in earnings) and its valuation is demanding (P/E 40.5). Progress in its pipeline, especially LEQEMBI and kidney disease data, is positive, but regulatory risk in the pharmaceutical sector is a drag.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.2 |
| Quality / Moat | 5.5 |
| Valuation | 4.8 |
| Growth | 2.6 |
| Dividend | 1.5 |
| Momentum | 8.9 |
| Risk & Context | 8.8 |
OVERALL SCORE: 5.6/10
Context and risks
Moderate regulatory risk in the pharmaceutical sector due to drug pricing pressure in the US (Inflation Reduction Act) and dependence on FDA approvals for its pipeline. Governance in the US is solid, but exposure to drug pricing policies is a relevant sector risk.
News considered in the analysis
- Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack — Resultados del segundo trimestre que superan las expectativas, lo que refuerza la confianza en la ejecución operativa.
- How Investors May Respond To Biogen (BIIB) Advancing At-Home LEQEMBI Pen And Kidney Disease Data — El avance del dispositivo de administración en el hogar para LEQEMBI y los datos positivos en nefrología amplían el potencial comercial de su cartera.
- Novo Nordisk Stock Slides After Unveiling Long Term Pipeline Growth Targets — Noticia sobre un competidor directo (Novo Nordisk) que no afecta directamente a los fundamentales de Biogen.
- Biogen (BIIB) Posts New Kidney Trial Data, Is It Still 5% Undervalued? — Los nuevos datos de un ensayo en nefrología son positivos, aunque el impacto en valoración es moderado y ya está parcialmente descontado.
- Novo Nordisk shares plunge over 7% as new targets fail to reassure investors — Caída de un competidor por sus propias previsiones; sin impacto directo en Biogen.
Verdict: Hold positions; the pipeline potential and positive momentum are offset by declining earnings and high valuation.
Main risk: The main risk is the dependence on regulatory approval and commercial adoption of LEQEMBI for Alzheimer's, whose failure or slow launch could significantly impact growth expectations.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →